Quarterly ResultMay 11, 2026, 08:07 AM
Heron Therapeutics Q1 Net Loss $(8.1)M; Sales Down 10.8%
AI Summary
Heron Therapeutics reported a net loss of $8.1 million for Q1 2026, a significant decline from a net income of $2.6 million in Q1 2025. Net product sales decreased by 10.8% to $34.7 million. While sales of ZYNRELEF and APONVIE increased, CINVANTI and SUSTOL sales saw substantial declines. The company ended the quarter with $44.8 million in cash, cash equivalents, and short-term investments, and management believes this is sufficient for at least one year.
Key Highlights
- Net product sales decreased 10.8% to $34.7 million in Q1 2026 from $38.9 million in Q1 2025.
- Reported a net loss of $8.1 million, or $(0.04) per basic share, compared to a net income of $2.6 million, or $0.02 per basic share, in Q1 2025.
- ZYNRELEF net product sales increased 27.3% to $10.2 million in Q1 2026.
- APONVIE net product sales rose 50.2% to $3.4 million in Q1 2026.
- CINVANTI net product sales decreased 20.2% to $20.5 million in Q1 2026.
- SUSTOL net product sales fell 80.9% to $0.5 million in Q1 2026.
- Net cash used in operating activities improved to $(1.5) million in Q1 2026 from $(8.9) million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $44.8 million as of March 31, 2026.
Price Impact
More from HRTX